DUBLIN--(
BUSINESS WIRE
)--The
"Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023"
report has been added to
ResearchAndMarkets.com's
offering.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2016.
There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.
Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.
The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.
Chapter 4 provides a review of the leading Joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.
The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.
Key benefits
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:
In-depth understanding of joint venture partnering deal trends since 2016, with real life case studies
Comprehensive listing of all joint venture deals since 2016, together with deal terms, value and press release
Comprehensive access to actual joint venture contracts entered into by the world's life science companies
Insight into the terms included in a joint venture agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes:
Trends in joint venture dealmaking in the biopharma industry since 2016
Case studies of real-life joint venture deals
Comprehensive listing of joint venture deals since 2016
Access to joint venture contract documents
The leading joint venture deals by value since 2016
Most active joint venture dealmakers since 2016
The leading joint venture partnering resources
In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for joint venture deals.
Companies Mentioned
3SBio
1717 Life Science Ventures
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A*STAR' Institute of Molecular and Cell Biology
A2A Pharmaceuticals
AAP Implantate AG
Abbott Laboratories
Abbvie
Abilita Bio
ABIVAX
Abzena
Accellix
Accuray
Acnos Pharma
Adept Neuro
Adisseo
Advanced Prenatal Therapeutics
Advanced Technologies Solutions
Aequus Pharmaceuticals
Agilis Biotherapeutics
AgonOx
AirWare Labs
Aitbiotech
Akers Biosciences
AKESOgen
Aleafia Health
Aleva Neurotherapeutics
Allied-Bristol Life Sciences
Allied Minds
Ally Bridge Group
Altus Formulation
Alzheimer's Association
Alzheimer's Research UK
Amarantus BioSciences
Amendia
American Diabetes Association
AmerisourceBergen
Amunix
Amyris
AnaBios
Anokion
Antitope
Antoxerene
Apax Partners
Aphria
Arbele
Arbutus
ARCH Personalized Medicine Initiative
Aridis Pharmaceuticals
Aruvant Sciences
Arvinas
Ascendance Biotechnology
Ascendis Pharma
Asklepios Biopharmaceutical
Aslan Pharma
Astellas Pharma
AstraZeneca
ATAI Life Sciences
Athenex
ATL Technology
Atomwise
Atrapos Therapeutics
Atropos Therapeutics
Auramedi Farmaceutica
Autobio Diagnostics
AUT Roche Diagnostics Laboratory
AUT University
Auxly Cannabis Group
Avacta
Avactis Biosciences
Avalon GloboCare
Avivagen
Avvinity Therapeutics
Axis Therapeutics
Bain Capital
Baxter International
Bayer
Baylor College of Medicine
Baylor Miraca Genetics Laboratories
B Braun
B Braun CeGaT
Beckley Canopy Therapeutics
Beckley Foundation
Becton Dickinson
BeiGene
Beijing Genomics Institute (BGI)
Beijing Leadman Biochemistry
Berry Genomics
Betaliq
BevCanna
BGI Tech Solutions
BHB Therapeutics
Bill and Melinda Gates Foundation
Bio-Techne
BioAmber
Biodist
Biodyne USA
BioFields
Biogen
Biohealth Innovation
BioHeart
BioLife Solutions
BioLight
BiolineRX
biologistex CCM
BioMed X Innovation Center
Biomerics
BioMotiv
BioPharma Services
Blackstone
Blockshine Technology
Bloomage BioTechnology
Bloom Burton
BLP Management
Blueberries Medical
Boehringer Ingelheim
Breakthrough Diagnostics
Brigham and Women's Hospital
Bristol-Myers Squibb
Broad Institute
Buchang Pharmaceutical
Buck Institute for Age Research
Bukwang Pharmaceuticals
Button Capital
Calysta Energy
Cancer Research Technology
Cannabics Pharmaceuticals
Cannabis Biocare
Cannabis Therapeutics
CannAmerica Brands
CannaRoyalty
Canopy Health Innovations
Capna Intellectual
Capnia
Cardio3 Biosciences Asia Holdings
Casebia Therapeutics
Catapult Therapy TCR
CB2 Therapeutics
CBDerma Technology
CBDistribution
Cedar Gate Technologies
CeGaT
Cell Therapy Catapult
Celyad
Centauri Therapeutics
Centene
Center for Genetic Engineering and Biotechnology (Cuba)
Centre for Commercialization of Regenerative Medicine (CCRM)
Centro de Inmunolgia Molecular
Cerevel Therapeutics
Cesca Therapeutics
Chan Soon-Shiong Institute of Molecular Medicine
ChemAxon
Children's Medical Research Institute
Chimera Biotec
China-Israel Biological Technology
China-Singapore Guangzhou Knowledge City
China Isotope And Radiation
Chinese Academy of Science
Chinese Future Industry Investment Fund
Chongqing PSK-Health Sci-tech Development
Cincinnati Children's Hospital Medical Center
City of Hope
CJ CheilJedang
ClearPath
Cloaked Therapeutics
Co-Diagnostics
Cohen Veterans Bioscience
Cold Spring Harbor
Colibri Heart Valve
Collagen Solutions Plc
Columbus Venture Partners
Concentrics Research
Consortium AI
Corestone Biosciences
Cornerstone Animal Health
Corning
Covenant Animal Health Partners
Cre8ive
CRISPR Therapeutics
CureCell
Cyclica
CytoBioscience
Cytotheryx
Cytovant Sciences
Daewoong Pharmaceutical
Dance Biopharm
Dasman Diabetes Institute
David Snow
Deerfield Management
DemeRx
Demetra
Denka
Denka-KEW Genomics
DepYmed
DIAN Diagnostics
Diavax Biosciences
Dixi
Dizal Pharmaceutical
DolCas-Tenshi Bioceuticals
DolCas Biotech
Dona Blanca
Dongbao
Dr. Walter Bell
Duke-NUS Graduate Medical School Singapore
Eastar Industries
Eastern Capital
Easton Pharmaceuticals
eCardio Diagnostics
Eddingpharm
Eden BioCell
Elanix Biotechnologies
Elevar Therapeutics
Eli Lilly
EMD Millipore
EMD Serono
Emergence Therapeutics
EmoCellix
Emory University
Emosis
Enigma Diagnostics
Enova Illumination
Entheogenix Biosciences
ERS Genomics
Evotec
ExCellThera
Exemplar Genetics
Facebook
Faes Farma
Faxian Therapeutics
Fedecore
Fedora Pharmaceuticals
FerGene
Ferring Pharmaceuticals
FJ Pharma
Flexpoint Ford
Flow Pharma
Fonterra
Food and Drug Administration (FDA)
FORMA Therapeutics
Fortress Biotech
Fosun Pharmaceutical
FoxBio
Fox Chase Cancer Center
Fraunhofer Institute for Microelectronic Circuits and Systems
Frazier Healthcare Ventures
Fresenius Kabi Pharmaceuticals
Frontage Laboratories
FSD Pharma
Futura Medical
Fuzionaire Diagnostics
Fuzionaire Radioisotope Technologies
G-treeBNT
Galectin Sciences
Galectin Therapeutics
Galvani Bioelectronics
Gauss Surgical
Genentech
Gene Therapy Research Institution
Genetic Technologies
Genevant Sciences
Genome Institute of Singapore
Genomix Scientific
Gentag
GeoVax
German Research Center for Artificial Intelligence
Gerresheimer
GHO Capital
Ginkgo BioWorks
GlaxoSmithKline
For more information about this report visit
https://www.researchandmarkets.com/r/laae8e
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.